Content
German Inflation Up Again In August
Article By:
Carsten Brzeski
Read
Tuesday, August 30, 2022 9:09 AM EDT
The effect of the government's energy relief package was already waning ahead of the measures expiring tomorrow. Headline inflation increased in August on the back of higher gas and food prices as well as higher prices in the hospitality sector.
In this article: EWU
180 Life Sciences: Why Investors Should Take Notice
Article By:
Avisol Capital Partners
Read
Monday, August 15, 2022 11:32 AM EDT
180 Life Sciences is an under the radar stock worthy of a closer look. We sat down with CEO Dr. James Woody to dig deeper into ATNF to learn if the stock merits being added to your portfolio.
Gain Therapeutics: Reasons For Optimism
Article By:
Kate Hayden
Read
Wednesday, August 10, 2022 9:00 AM EDT
In biotechnology, potential rules. And in Gain's case, the potential to not just treat but functionally cure at least some forms of Parkinson's Disease is strong enough to weather early-stage challenges.
Nokia Corporation: Repurchase Of Own Shares On 5 August, 2022
Article By:
NASDAQ GlobeNewswire
Read
Saturday, August 6, 2022 7:37 AM EDT
Total cost of transactions executed on 5 August 2022 was EUR 1,216,370.40. After the disclosed transactions, Nokia Corporation holds 77,822,700 treasury shares.
In this article: NOK
Binance And Mastercard Launch Prepaid Card In Argentina To Bridge Cryptocurrencies And Everyday Purchases
Article By:
PR Newswire
Read
Thursday, August 4, 2022 10:00 AM EDT
The country is the first in Latin America to have the product, the card is in beta phase and will be widely available in the coming weeks.
SurgePays Will Surge Ahead As Subscribers Flock To The Company
Article By:
Shareholders Unite
Read
Tuesday, August 2, 2022 11:43 AM EDT
SurgePays is starting to look quite attractive, so we took a deep dive into SURG and spoke to management to get the inside scoop on what to expect.
In this article: SURG
SurgePays Is An Undiscovered Diamond With An Upward Trend
Article By:
Moon Kil Woong
Read
Thursday, July 21, 2022 1:38 PM EDT
SurgePays is an undiscovered diamond with demand, with upcoming profitability, and with a positive stock track.
In this article: SURG
SurgePays Passes 150,000 Mobile Broadband Subscribers
Article By:
TalkMarkets Newswire
Read
Thursday, July 14, 2022 10:11 AM EDT
SurgePays, a technology and telecommunications company focused on the underbanked and underserved, announces it exceeded 150,000 subscribers in its mobile broadband subscriber business SurgePhone Wireless LLC.
In this article: SURG
Awakn Life Sciences Q1 Revenue Increased 24%
Article By:
Lorimer Wilson
Read
Sunday, June 19, 2022 12:02 AM EDT
Awakn Life Sciences is a biotechnology company, researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder and its revenue increased 24% from the previous quarter.
AMD Details Strategy To Drive Next Phase Of Growth Across $300 Billion Market For High-Performance And Adaptive Computing Solutions
Article By:
NASDAQ GlobeNewswire
Read
Thursday, June 9, 2022 11:00 PM EDT
At its analysts day Thursday, AMD unveiled next-generation hardware and software roadmaps, and an expanded product portfolio addressing new markets.
In this article: AMD
New York’s Financial Regulator Releases Guidelines For Stablecoin Issuers
Article By:
Crypto Adventure
Read
Thursday, June 9, 2022 2:48 PM EDT
The New York State Department of Financial Services (DFS) has announced new regulatory guidance for the issuance of stablecoins pegged to the U.S. dollar in the state.
In this article: UST-X
Akerna Announces Corporate Restructuring
Article By:
NASDAQ GlobeNewswire
Read
Sunday, May 29, 2022 11:37 AM EDT
Consolidation, headcount, and reductions expected to yield material annualized cost savings, effective July 1, 2022.
In this article: KERN
Trulieve Q1 Financials Report Record Revenue And EBITDA; Major Reduction In Net Loss
Article By:
Lorimer Wilson
Read
Monday, May 16, 2022 2:29 AM EDT
Truilive's stock price was up 9.6% as of the end of trading this past Friday based on the impressive Q1 financial results but it remains -38.6% YTD and -72.0% from its high in 2021.
In this article: TCNNF
Protalix PRX-102: Likely Approval Could Be A Game Changer
Article By:
Shareholders Unite
Read
Monday, May 2, 2022 9:02 AM EDT
Protalix's PRX-102 drug stands a good chance of being accepted against Fabry disease, with three P3 trials delivering good results.
